DWTX · Dogwood Therapeutics, Inc.
$1.15
-0.06 (-4.96%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Accordingly, there is substantial doubt about the Company's ability to operate as a going concern within one year after the issuance date of these condensed consolidated financial statements.”View the 10-Q filed Aug 14, 2026
Market Cap
$39.09M
Shares
33.99M
Volume · Oct 20
50.35K
Avg daily vol (3M)
69.14K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.15
Open$1.22
Day$1.14–1.26
52W close$1.15–6.82
Avg vol 30d74K
Short int39K · 0.1% float · 1.0d
Short vol51%
Last earningsMay 14, 2026
DataDec 2020–Oct 2026
Filing10-Q · Aug 14
Up next
Next earnings call
Dec 24, 2026
Est · unconfirmed
· in 9 wks
filed Aug 14, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$36.04M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
0.4
Trailing earnings · reciprocal yield 233.1%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$9.61M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1,685.8%
Year over year · more shares
Price change (1Y)
-79.0%
Trailing year
Short interest
0.1%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 17.3 · elevated
Equity put/call 0.56
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−44%
below
Price vs 50-day avg
−37%
below
RSI (14)
24
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−24%
trailing
6-month return
−15%
trailing
YTD return
−72%
this year
Relative strength
−23%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Flat
1 of 15 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.11% of float · ▼ -47.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
15 holders — mid 3-yr range
Squeeze score
22
low risk · 0–100
Fundamentals
EPS growth
+43%
Y/Y
Balance sheet
$6.5M
net cash
Quant / Vol
risk profile
Volatility
87%
annualized · 1-yr
Max drawdown
−83%
past year
ATR
12.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−44%
Bearish
Price vs 50-day avg
−37%
Bearish
RSI (14)
24
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow
Flat
1 of 15 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.11% of float · ▼ -47.6% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
15 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $7
vs 200-day avg -44%
vs 50-day avg -37%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash on hand | $9.6M | Q2 2026 | — |
| potential value of worldwide development and commercialization partnership for legacy antiviral | $100M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DWTX
this stock
Dogwood Therapeutics, Inc.
|
$39.09M | -72.4% | — | — | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.07B | +13.5% | +46.2% | 29.9 | 1.8% |
|
MRNA
Moderna, Inc.
|
$90.58B | +720.9% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$80.51B | +4.6% | +20.8% | 19.4 | 2.1% |
|
CSLLY
Csl Ltd
|
$66.34B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
SEC Filings
Latest
8-K
- Filed
- Oct 19, 2026
- This year
- 18
Dogwood Therapeutics entered a Subscription Agreement on October 19, 2026, to issue 4,098,360 shares of common stock to Sealbond Limited at $1.22 per share for an aggregate purchase price of $4,999,999.20, expected to close on or before October 29, 2026.
ViewEarnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DWTX | -11.5% | -23.8% | -14.8% | -14.8% | -72.4% |
| SPY | -1.2% | -0.6% | +8.1% | +0.8% | +12.8% |
| vs SPY | -10.4% | -23.3% | -22.9% | -15.7% | -85.1% |